X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration will include co-development of novel precision antibacterials, including first-in-class novel lysins (engineered precision enzymes), targeting indications prone to antimicrobial-resistant infections.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Recipient: Precisio Biotix Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 14, 2024
Details:
The collaboration aims to evaluate NXP800, an oral small molecule, in an Investigator-sponsored clinical trial in cholangiocarcinoma. The FDA granted Orphan Drug Designation for the treatment of cholangiocarcinoma.
Lead Product(s): NXP800
Therapeutic Area: Oncology Product Name: NXP800
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Nuvectis Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 18, 2023
Details:
QSIVA is a combination of phentermine, a sympathomimetic amine anorectic and topiramate extended-release, an antiepileptic drug. It is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity.
Lead Product(s): Phentermine,Topiramate
Therapeutic Area: Nutrition and Weight Loss Product Name: Qsiva
Highest Development Status: Phase IVProduct Type: Small molecule
Recipient: Vivus
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Details:
INSB400 is an early-development product focused on local delivery of cancer drugs with a precise elution rate over a pre-programmed period of time. INSB400 is being designed to avoid severe patient adverse events associated with systemic exposure to chemotherapeutic agents.
Lead Product(s): INSB400
Therapeutic Area: Oncology Product Name: INSB400
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: InSitu Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 22, 2022
Details:
By delivering a broad repertoire of tumor associated antigens, ASEL and neoantigens enhanced by APOBEC mutagenesis, strong T-cell responses have been demonstrated pre-clinically without the need for identification of patient specific tumor associated antigens.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: MGFB
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 08, 2022
Details:
The focus will be on therapies derived from biologics — cells, blood, enzymes, tissues, genes, or genetically engineered cells — for use in medicines. In addition, the collaboration seeks to advance biologic discoveries toward early stage clinical trials.
Lead Product(s): Undisclosed
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Resilience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 15, 2022
Details:
The company is developing latiglutenase (IMGX003) for celiac disease therapy. ImmunogenX is also developing a diagnostic tool for celiac disease management as a minimally-invasive monitor of villus health to follow the state of recovery of a celiac patient.
Lead Product(s): Latiglutenase
Therapeutic Area: Gastroenterology Product Name: IMGX003
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: ImmunogenX
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2022
Details:
Under the terms of the collaboration agreement, VeriSIM will leverage its proprietary BIOiSIM™ platform and Translational Index™ approach to reduce the number of outsourced preclinical experiments and help de-risk R&D decisions early-on to ensure expedited development.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Recipient: VeriSIM
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 28, 2022
Details:
PneoVCA is designed to target certain proteins (neoantigens) on individuals’ tumor cells. Combination immunotherapy with mAB, such as pembrolizumab, may help the body’s immune system attack the cancer and thereby interfere with ability of tumor cells to grow and spread.
Lead Product(s): PneoVCA,Pembrolizumab
Therapeutic Area: Oncology Product Name: PneoVCA
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: Pepscan
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
Details:
As part of the collaboration, NaNotics will provide its core nano-depletion platform and Mayo Clinic will provide an antibody of its own design against PD-L1, which will be specific to sPD-L1 once incorporated into a NaNot.
Lead Product(s): NaNot-antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: NaNotics LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
